Takeda Pharmaceutical Company Limited

Takeda is a global biopharmaceutical company that discovers, develops, and commercializes medicines, including treatments in oncology, rare genetics and hematology, neuroscience, and gastroenterology.

Identity plus TickerGrove reporting or verified official materials.

Description: Takeda Pharmaceutical Company Limited Form 20-F business description

CompareShare by email

Latest verified period

FDA Mimrylo (rusfertide) approval August 28, 2026; Takeda same-day release

IR release · filed or released 2026-08-28

Mimrylo required no phlebotomies during the 32-week period: 76.9%
Placebo required no phlebotomies during the 32-week period: 32.9%
VERIFY adults: 293

Open primary document

Market price

Latest quoteOpens Google

Primary sources

Go to the record

Open filings and issuer materials directly before relying on a summary.

SEC filingsCIK 0001395064 Investor relationsOfficial issuer site

Additional verified figures

More from the same period

Figures come from the verified IR release for FDA Mimrylo (rusfertide) approval August 28, 2026; Takeda same-day release. Empty statement modules are not invented to look complete. EPS and Revenue follow the filing labels.

Mimrylo starting dose: 19 mg

TickerGrove coverage

Latest on Takeda Pharmaceutical Company Limited

Product/Regulation

FDA approves Mimrylo, the first hepcidin mimetic for adult polycythemia vera

The Food and Drug Administration approved Mimrylo (rusfertide) on August 28, 2026, for adults with polycythemia vera. In the VERIFY trial of 293 adults, 76.9% on Mimrylo required no phlebotomies during the 32-week period, compared with 32.9% on placebo. Takeda Pharmaceuticals America holds the NDA. Takeda said the approval does not change its forecast for the fiscal year ending March 31, 2027.

Published 08-28-2026 · U.S. Food and Drug Administration

Understand the company